biostudies-literatureUnknown13Zhou YCutaneous melanoma (CM) is an aggressive form of malignancy with poor prognostic value. Cuproptosis is a novel type of cell death regulatory mechanism in tumors. However, the role of cuproptosis-related long noncoding RNAs (lncRNAs) in CM remains elusive. The cuproptosis-related lncRNAs were identified using the Pearson correlation algorithm. Through the univariate and multivariate Cox regression analysis, the prognosis of seven lncRNAs associated with cuproptosis was established and a new risk model was constructed. ESTIMATE, CIBERSORT, and single sample gene set enrichment analyses (ssGSEA) were applied to evaluate the immune microenvironment landscape. The Kaplan-Meier survival analysis revealed that the overall survival (OS) of CM patients in the high-risk group was remarkably lower thFrontiers in genetics959456https://www.ebi.ac.uk/biostudies/studies/S-EPMC9354044biostudies-literatureA novel risk model based on cuproptosis-related lncRNAs predicted prognosis and indicated immune microenvironment landscape of patients with cutaneous melanoma.PMC9354044Shu QLi JWang CFu ZXie MGu JChen YZhou YfalseA novel risk model based on cuproptosis-related lncRNAs predicted prognosis and indicated immune microenvironment landscape of patients with cutaneous melanoma.Cutaneous melanoma (CM) is an aggressive form of malignancy with poor prognostic value. Cuproptosis is a novel type of cell death regulatory mechanism in tumors. However, the role of cuproptosis-related long noncoding RNAs (lncRNAs) in CM remains elusive. The cuproptosis-related lncRNAs were identified using the Pearson correlation algorithm. Through the univariate and multivariate Cox regression analysis, the prognosis of seven lncRNAs associated with cuproptosis was established and a new risk model was constructed. ESTIMATE, CIBERSORT, and single sample gene set enrichment analyses (ssGSEA) were applied to evaluate the immune microenvironment landscape. The Kaplan-Meier survival analysis revealed that the overall survival (OS) of CM patients in the high-risk group was remarkably lower th2022-01-01T00:00:00Z20222026-07-14T15:59:17.385Z2025-02-19T04:54:04.299ZS-EPMC93540443593803610.3389/fgene.2022.959456